Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 3, 2019

Neurocrine enters $1.7bn epilepsy therapies deal with Xenon

Neurocrine Biosciences has signed a licence and collaboration agreement valued at more than $1.7bn with Xenon Pharmaceuticals to develop epilepsy treatments.

Neurocrine Biosciences has signed a licence and collaboration agreement valued at more than $1.7bn with Xenon Pharmaceuticals to develop epilepsy treatments.

As part of the deal, Neurocrine receives an exclusive licence to a selective Nav1.6 sodium channel inhibitor candidate, XEN901. The drug is being developed to potentially treat SCN8A developmental and epileptic encephalopathy (SCN8A-DEE) and other epilepsies.

Neurocrine also gets a licence to exclusively develop pre-clinical compounds, including selective Nav1.6 and dual Nav1.2 / 1.6 inhibitors.

Furthermore, the agreement includes a multi-year research alliance to discover and develop additional Nav1.6 and Nav1.2 / 1.6 inhibitors.

Neurocrine Biosciences CEO Kevin Gorman said: “The agreement with Xenon strengthens Neurocrine Biosciences’ diverse and growing pipeline and reinforces our long-term commitment of becoming a leading neuroscience-focused biopharmaceutical company.”

Neurocrine will bear developments costs of all programmes covered under the partnership. The company will pay $50m to Xenon, including an upfront cash payment of $30m and an equity investment of $20m.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Furthermore, Neurocrine will pay up to $25m upon the US Food and Drug Administration (FDA) acceptance of XEN901’s investigational new drug (IND) application. Of this payment, 55% will be paid as an equity investment.

The company expects to file an IND next year for the clinical trial of XEN901 in SCN8A-DEE patients.

Xenon will also gain up to $1.7bn in development, regulatory and commercial milestones associated with XEN901 and additional licenced Nav1.6 or Nav1.2 / 1.6 inhibitors, as well as sales royalties.

The company holds an option to fund 50% of the US development costs of a product candidate and will, in turn, receive royalties for XEN901 sales in the country.

Xenon Pharmaceuticals CEO Dr Simon Pimstone said: “Importantly, this collaboration represents a significant investment in XEN901 and Xenon’s earlier-stage Nav1.6 and Nav1.2 / 1.6 inhibitor programs and allows for a broader development of these promising compounds than we could accomplish independently.

“Furthermore, the additional capital from this transaction will support our efforts to advance and expand our proprietary pipeline.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy